New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 4, 2014
05:38 EDTSZYMSolazyme downgraded to Neutral from Buy at Goldman
Goldman downgraded Solazyme citing valuation and limited upside potential. The firm keeps a $13.50 price target for shares.
News For SZYM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
16:43 EDTSZYMSolazyme begins restructuring plan to reduce 2015 operating expenses by $18.0M
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use